Exact Mass: 407.2209
Exact Mass Matches: 407.2209
Found 34 metabolites which its exact mass value is equals to given mass value 407.2209,
within given mass tolerance error 0.001 dalton. Try search metabolite list with more accurate mass tolerance error
0.0002 dalton.
1,3(2H,4H)-Isoquinolinedione, 2-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-4,4-dimethyl-
2-{2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl}-4,4-dimethyl-1,2,3,4-tetrahydroisoquinoline-1,3-dione
D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists ARC 239 is an α2B/C-adrenergic receptor antagonist with pKi of 7.06 and 6.95 for rat kidney α2B and human α2C, respectively. ARC 239 also inhibits 5-HT1A receptor with a Ki of 63.1 nM[1][2].
(3Z,6S)-3-{{2-(1,1-dimethylprop-2-en-1-yl)-7-[(2E)-4-hydroxy-3-methylbut-2-en-1-yl]-1H-indol-3-yl}methylidene}-6-methylpiperazine-2,5-dione|variecolorin M
(3Z,6S)-3-{{2-(1,1-dimethylprop-2-en-1-yl)-7-[(2E)-4-hydroxy-3-methylbut-2-en-1-yl]-1H-indol-3-yl}methylidene}-6-methylpiperazine-2,5-dione|variecolorin M
(3S,6S)-3-((1,7-dihydro-7,7-dimethyl-2-(2-methylbut-3-en-2-yl)pyrano[2,3-g]indol-3-yl)methyl)-6-methylpiperazine-2,5-dione|talathermophilin D
(3S,6S)-3-((1,7-dihydro-7,7-dimethyl-2-(2-methylbut-3-en-2-yl)pyrano[2,3-g]indol-3-yl)methyl)-6-methylpiperazine-2,5-dione|talathermophilin D
(2S,4R)-N-[(1R,2R)-2-hydroxy-1-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-methylsulfanyloxan-2-yl]propyl]-1-methyl-4-propylpyrrolidin-1-ium-2-carboxamide
(2S,4R)-N-[(1R,2R)-2-hydroxy-1-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-methylsulfanyloxan-2-yl]propyl]-1-methyl-4-propylpyrrolidin-1-ium-2-carboxamide
N-butyl-3-[1-[(2,5-dimethylphenyl)methyl]-2,4-dioxo-3-quinazolinyl]propanamide
N-butyl-3-[1-[(2,5-dimethylphenyl)methyl]-2,4-dioxo-3-quinazolinyl]propanamide
ethyl 4-(2,5-dimethylphenyl)-6-[[(4-methylphenyl)methylamino]methyl]-2-oxo-3,4-dihydro-1H-pyrimidine-5-carboxylate
ethyl 4-(2,5-dimethylphenyl)-6-[[(4-methylphenyl)methylamino]methyl]-2-oxo-3,4-dihydro-1H-pyrimidine-5-carboxylate
(2R,3S)-2-[(dimethylamino)methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-8-(2-phenylethynyl)-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one
(2R,3S)-2-[(dimethylamino)methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-8-(2-phenylethynyl)-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one
[(2S,3S)-2-(hydroxymethyl)-1-(4-oxanylmethyl)-3-phenyl-1,6-diazaspiro[3.3]heptan-6-yl]-pyridin-4-ylmethanone
[(2S,3S)-2-(hydroxymethyl)-1-(4-oxanylmethyl)-3-phenyl-1,6-diazaspiro[3.3]heptan-6-yl]-pyridin-4-ylmethanone
(2R,3R,3aS,9bS)-N-cyclobutyl-3-(hydroxymethyl)-6-oxo-1-(2-phenylethyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide
(2R,3R,3aS,9bS)-N-cyclobutyl-3-(hydroxymethyl)-6-oxo-1-(2-phenylethyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide
(2S,3S,3aR,9bR)-N-cyclobutyl-3-(hydroxymethyl)-6-oxo-1-(2-phenylethyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide
(2S,3S,3aR,9bR)-N-cyclobutyl-3-(hydroxymethyl)-6-oxo-1-(2-phenylethyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide
[(1S)-7-methoxy-2-[(3-methoxyphenyl)methyl]-1-methyl-1-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,3-azetidine]yl]methanol
[(1S)-7-methoxy-2-[(3-methoxyphenyl)methyl]-1-methyl-1-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,3-azetidine]yl]methanol
[(1R)-7-methoxy-2-[(3-methoxyphenyl)methyl]-1-methyl-1-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,3-azetidine]yl]methanol
[(1R)-7-methoxy-2-[(3-methoxyphenyl)methyl]-1-methyl-1-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,3-azetidine]yl]methanol
[(2S,3R)-2-(hydroxymethyl)-1-(4-oxanylmethyl)-3-phenyl-1,6-diazaspiro[3.3]heptan-6-yl]-pyridin-4-ylmethanone
[(2S,3R)-2-(hydroxymethyl)-1-(4-oxanylmethyl)-3-phenyl-1,6-diazaspiro[3.3]heptan-6-yl]-pyridin-4-ylmethanone
(6R,7R,8R)-8-(hydroxymethyl)-7-[4-(4-methylphenyl)phenyl]-2-oxo-N-propan-2-yl-1,4-diazabicyclo[4.2.0]octane-4-carboxamide
(6R,7R,8R)-8-(hydroxymethyl)-7-[4-(4-methylphenyl)phenyl]-2-oxo-N-propan-2-yl-1,4-diazabicyclo[4.2.0]octane-4-carboxamide
1,3(2H,4H)-Isoquinolinedione, 2-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-4,4-dimethyl-
1,3(2H,4H)-Isoquinolinedione, 2-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-4,4-dimethyl-
D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists ARC 239 is an α2B/C-adrenergic receptor antagonist with pKi of 7.06 and 6.95 for rat kidney α2B and human α2C, respectively. ARC 239 also inhibits 5-HT1A receptor with a Ki of 63.1 nM[1][2].
(3s,6s)-3-{[7,7-dimethyl-2-(2-methylbut-3-en-2-yl)-1h-chromeno[5,6-b]pyrrol-3-yl]methyl}-6-methyl-3,6-dihydropyrazine-2,5-diol
(3s,6s)-3-{[7,7-dimethyl-2-(2-methylbut-3-en-2-yl)-1h-chromeno[5,6-b]pyrrol-3-yl]methyl}-6-methyl-3,6-dihydropyrazine-2,5-diol
5-hydroxy-3-{[7-(4-hydroxy-3-methylbut-2-en-1-yl)-2-(2-methylbut-3-en-2-yl)-1h-indol-3-yl]methylidene}-6-methyl-1,6-dihydropyrazin-2-one
5-hydroxy-3-{[7-(4-hydroxy-3-methylbut-2-en-1-yl)-2-(2-methylbut-3-en-2-yl)-1h-indol-3-yl]methylidene}-6-methyl-1,6-dihydropyrazin-2-one
(1r,10s,11r,12s,22r)-16,17-dimethoxy-9-oxa-4,13-diazahexacyclo[9.8.3.2¹⁰,¹³.0¹,¹².0⁶,²².0¹⁴,¹⁹]tetracosa-6,14(19),15,17-tetraene-4-carbonitrile
(1r,10s,11r,12s,22r)-16,17-dimethoxy-9-oxa-4,13-diazahexacyclo[9.8.3.2¹⁰,¹³.0¹,¹².0⁶,²².0¹⁴,¹⁹]tetracosa-6,14(19),15,17-tetraene-4-carbonitrile
n-[3-(n-{4-[(hydroxymethylidene)amino]butyl}-3-phenylprop-2-enamido)propyl]benzenecarboximidic acid
n-[3-(n-{4-[(hydroxymethylidene)amino]butyl}-3-phenylprop-2-enamido)propyl]benzenecarboximidic acid
(3z,6s)-3-({5-[(2r)-2-hydroxy-3-methylbut-3-en-1-yl]-2-(2-methylbut-3-en-2-yl)-1h-indol-3-yl}methylidene)-6-methyl-6h-pyrazine-2,5-diol
(3z,6s)-3-({5-[(2r)-2-hydroxy-3-methylbut-3-en-1-yl]-2-(2-methylbut-3-en-2-yl)-1h-indol-3-yl}methylidene)-6-methyl-6h-pyrazine-2,5-diol
3-{[7,7-dimethyl-2-(2-methylbut-3-en-2-yl)-1h-chromeno[5,6-b]pyrrol-3-yl]methyl}-6-methyl-3,6-dihydropyrazine-2,5-diol
3-{[7,7-dimethyl-2-(2-methylbut-3-en-2-yl)-1h-chromeno[5,6-b]pyrrol-3-yl]methyl}-6-methyl-3,6-dihydropyrazine-2,5-diol
16,17-dimethoxy-9-oxa-4,13-diazahexacyclo[9.8.3.2¹⁰,¹³.0¹,¹².0⁶,²².0¹⁴,¹⁹]tetracosa-6,14(19),15,17-tetraene-4-carbonitrile
16,17-dimethoxy-9-oxa-4,13-diazahexacyclo[9.8.3.2¹⁰,¹³.0¹,¹².0⁶,²².0¹⁴,¹⁹]tetracosa-6,14(19),15,17-tetraene-4-carbonitrile
3-({5-[(3,3-dimethyloxiran-2-yl)methyl]-2-(2-methylbut-3-en-2-yl)-1h-indol-3-yl}methylidene)-5-hydroxy-6-methyl-1,6-dihydropyrazin-2-one
3-({5-[(3,3-dimethyloxiran-2-yl)methyl]-2-(2-methylbut-3-en-2-yl)-1h-indol-3-yl}methylidene)-5-hydroxy-6-methyl-1,6-dihydropyrazin-2-one
(3z,6s)-3-({7-[(2e)-4-hydroxy-3-methylbut-2-en-1-yl]-2-(2-methylbut-3-en-2-yl)-1h-indol-3-yl}methylidene)-6-methyl-6h-pyrazine-2,5-diol
(3z,6s)-3-({7-[(2e)-4-hydroxy-3-methylbut-2-en-1-yl]-2-(2-methylbut-3-en-2-yl)-1h-indol-3-yl}methylidene)-6-methyl-6h-pyrazine-2,5-diol
5-hydroxy-6-methyl-3-{[5-(3-methyl-2-oxobutyl)-2-(2-methylbut-3-en-2-yl)-1h-indol-3-yl]methylidene}-1,6-dihydropyrazin-2-one
5-hydroxy-6-methyl-3-{[5-(3-methyl-2-oxobutyl)-2-(2-methylbut-3-en-2-yl)-1h-indol-3-yl]methylidene}-1,6-dihydropyrazin-2-one
1-(3-{[(2z,5s)-3,6-dihydroxy-5-methyl-5h-pyrazin-2-ylidene]methyl}-2-(2-methylbut-3-en-2-yl)-1h-indol-5-yl)-3-methylbutan-2-one
1-(3-{[(2z,5s)-3,6-dihydroxy-5-methyl-5h-pyrazin-2-ylidene]methyl}-2-(2-methylbut-3-en-2-yl)-1h-indol-5-yl)-3-methylbutan-2-one
(3z)-3-({5-[(3,3-dimethyloxiran-2-yl)methyl]-2-(2-methylbut-3-en-2-yl)-1h-indol-3-yl}methylidene)-6-methyl-6h-pyrazine-2,5-diol
(3z)-3-({5-[(3,3-dimethyloxiran-2-yl)methyl]-2-(2-methylbut-3-en-2-yl)-1h-indol-3-yl}methylidene)-6-methyl-6h-pyrazine-2,5-diol
5-hydroxy-3-{[5-(2-hydroxy-3-methylbut-3-en-1-yl)-2-(2-methylbut-3-en-2-yl)-1h-indol-3-yl]methylidene}-6-methyl-1,6-dihydropyrazin-2-one
5-hydroxy-3-{[5-(2-hydroxy-3-methylbut-3-en-1-yl)-2-(2-methylbut-3-en-2-yl)-1h-indol-3-yl]methylidene}-6-methyl-1,6-dihydropyrazin-2-one
n-{3-[(2e)-n-{4-[(hydroxymethylidene)amino]butyl}-3-phenylprop-2-enamido]propyl}benzenecarboximidic acid
n-{3-[(2e)-n-{4-[(hydroxymethylidene)amino]butyl}-3-phenylprop-2-enamido]propyl}benzenecarboximidic acid
